NovoCure (NVCR) Invested Capital (2014 - 2026)

NovoCure has disclosed Invested Capital across 13 years of filings, most recently posting $330.7 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $330.7 million, down 8.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $330.7 million (down 8.63% YoY), and the FY2025 annual result was $340.5 million, down 5.47% from the prior year.
• Invested Capital came in at $330.7 million for Q1 2026 at NovoCure, down from $340.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $1.0 billion in Q3 2022 to a low of $330.7 million in Q1 2026.
• The 5-year median for Invested Capital is $415.7 million (2023), against an average of $650.8 million.
• Across the five-year window, Invested Capital climbed 7.21% in 2022 and slumped 62.48% in 2024, its largest moves.
• NovoCure's Invested Capital stood at $1.0 billion in 2022, then slipped by 7.49% to $931.3 million in 2023, then plunged by 61.33% to $360.2 million in 2024, then slipped by 5.47% to $340.5 million in 2025, then declined by 2.86% to $330.7 million in 2026.
• The last three Invested Capital figures came in at $330.7 million (Q1 2026), $340.5 million (Q4 2025), and $341.3 million (Q3 2025), per Business Quant data.